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Abstract 22 
Objectives. Treatment of catheter-related bloodstream infections (CRBSI) is hampered by the 23 
characteristic tolerance of bacterial biofilms towards antibiotics. Our objective was to study 24 
the effect of the combination of antibiotics and the alkaline amino acid L-arginine or the 25 
cation chelator EDTA on the bacterial mortality of in vitro biofilms formed by an array of 26 
clinical strains responsible for CRBSI and representative of epidemiologically relevant 27 
bacterial species. 28 
Methods. Among 32 strains described in a previous clinical study, we focused on the most 29 
antibiotic-tolerant strains including coagulase-negative staphylococci (n=4), Staphylococcus 30 
aureus (n=4), Enterococcus faecalis (n=2), Pseudomonas aeruginosa (n=4) and 31 
Enterobacteriaceae (n=4). We used in vitro biofilm model (96-well plate assay) to study 32 
biofilm tolerance and we tested various combinations of antibiotics and non-antibiotic 33 
adjuvants. Gentamicin, amikacin or vancomycin were combined with disodium EDTA or L-34 
arginine during 24 hours, to reproduce the Antibiotic Lock Therapy (ALT) approach. 35 
Mortality of biofilm bacteria was measured by cfu quantification after a vigorous step of 36 
pipetting up and down in order to detach all biofilm bacteria from the surface of the wells. 37 
Results. Both of our adjuvant strategies significantly increased the effect of antibiotics 38 
against biofilms formed by Gram-positive and Gram-negative bacterial pathogens. The 39 
combination of gentamicin + EDTA was active against all tested strain but one P. aeruginosa. 40 
The combination of gentamicin + L-arginine was active against most of tested strains with the 41 
notable exception of coagulase-negative staphylococci for which no potentiation was 42 
observed. We also demonstrated that combination using amikacin + EDTA was active against 43 
Gram-negative bacteria and vancomycin + EDTA against Gram-positive bacteria. 44 
  
Conclusion. The addition of EDTA enhanced activity of gentamicin, amikacin, and 45 
vancomycin against biofilms formed by a wide spectrum of bacterial strains responsible for 46 
CRBSI. 47 
48 
  
Introduction 49 
Following an initial report in 19881, several studies demonstrated that antibiotic lock therapy 50 
(ALT) could be a therapeutic option in case of catheter-related bloodstream infection 51 
(CRBSI).1-3 ALT relies on the instillation of a small volume of highly concentrated antibiotic 52 
solution that dwells in the lumen of the catheter for 12 to 72 hours, in order to eradicate 53 
biofilm formed on the inner surface of the device.1,4 Indeed, most of treatment difficulties 54 
encountered during CRBSI are related to the presence of high cell density bacterial 55 
communities called bacterial biofilms.5 Biofilms display characteristic properties, including 56 
high tolerance towards antimicrobials that is defined by the ability of a subset of bacteria to 57 
survive in the presence of high concentration of antibiotics.6,7 58 
Recent IDSA guidelines recommend that ALT should be used in case of conservative 59 
treatment of uncomplicated long-term intravenous catheter-related bloodstream infections 60 
caused by coagulase-negative staphylococci or Enterobacteriaceae.8 This statement is based 61 
on different studies reporting salvage rates ranging from 80 to 90% in these situations.4 62 
However, other groups reported higher failure rates, even in case of coagulase-negative 63 
staphylococci infections.9,10 Furthermore, infections caused by Staphylococcus aureus or 64 
Pseudomonas aeruginosa are still considered to be at higher risk of treatment failure, despite 65 
recent encouraging results, for the latter case.4,11 Lastly, ALT requires locking the long-term 66 
intravenous catheter and thus reduces it’s availability for 7 to 14 days. Thus, there is a dire 67 
need for more efficient locks in order to improve biofilm eradication and reduce the time 68 
during which the catheter is unavailable. 69 
We previously demonstrated that 2 adjuvant strategies could be used to eradicate in 70 
vivo biofilms formed by various Gram-positive as well as Gram-negative nosocomial 71 
pathogens.12,13 The first strategy relies on the use of EDTA, a cation chelator that destabilizes 72 
the biofilm matrix.14 EDTA has been shown to increase the effect of gentamicin against in 73 
  
vitro biofilms but also to reduce the risk of CRBSI, when associated with minocycline.15,16 74 
Using a recently developed rat model of totally implantable venous access ports (TIVAPs), 75 
we showed that the combination of gentamicin and EDTA led to the quick and long-lasting 76 
eradication of biofilms formed in vivo by S. aureus, Staphylococcus epidermidis, Escherichia 77 
coli and P. aeruginosa.12,17 We also recently demonstrated that increasing the pH of a 78 
gentamicin-based lock solution with the clinically compatible alkaline amino-acid L-arginine 79 
led to the eradication of biofilms formed by S. aureus and E. coli.13 Indeed, alkaline pH 80 
increased the effect of aminoglycosides against planktonic as well as biofilm persister cells, 81 
both in vitro and in vivo.13 While these results were obtained with laboratory strains, we 82 
wondered whether these approaches could also be effective against a wide range of clinical 83 
strains responsible for CRBSI. Using clinical strains collected during a previously published 84 
prospective study, our main objective was to test in vitro the spectrum of action of the 85 
combination of gentamicin and EDTA or L-arginine.18 We also studied other combinations 86 
including antibiotics that are commonly used in case of CRBSI caused by gentamicin-87 
resistant strains, such as vancomycin or amikacin.4,19,20  88 
89 
  
Materials and methods 90 
Bacterial strains and growth conditions. Between February 2009 and October 2010, we 91 
conducted a prospective study in Beaujon Hospital, a tertiary teaching hospital, during which 92 
72 patients were included with a diagnosis of TIVAP-related infection.18 Bacterial strains 93 
were collected and stored at -80°C. For the present study, we decided to focus on patients 94 
included with a diagnosis of TIVAP-related BSI, i.e. the most relevant clinical indication for 95 
ALT (Supplementary Figure 1).4,8 We identified 43 cases of TIVAP-related BSI diagnosed 96 
at Beaujon and restricted our study to the most frequent bacterial pathogens responsible for 97 
CRBSI: Enterobacteriaceae, coagulase-negative staphylococci, S. aureus, P. aeruginosa and 98 
Enterococcus faecalis.18 Among our strains, some did not resume growth when bacterial 99 
stocks were streaked on blood agar plates. As a result, we recovered 32 strains that have been 100 
further studied (Table 1). 101 
Gram-positive bacteria (S. aureus, coagulase-negative staphylococci, E. faecalis) were grown 102 
in tryptic soy broth (TSB) supplemented with 0.25% (or 0.5% for E. faecalis) glucose (TSB 103 
glucose). Gram-negative bacteria (P. aeruginosa and Enterobacteriaceae) were grown in 104 
Lysogeny Broth (LB).21 Unless specified, all chemicals and antibiotics were purchased from 105 
Sigma-Aldrich (St. Louis, MO). EDTA was prepared as follow. Briefly, 0.5M stock solution 106 
of disodium EDTA was prepared in water. Then, NaOH was added dropwise in order to reach 107 
a pH of ~8. EDTA was used at the final concentration of 30 mg/mL. 108 
 109 
Determination of minimal inhibitory concentration Minimal inhibitory concentrations 110 
(MIC) were determined by broth microdilution in cation-adjusted Mueller-Hinton broth, as 111 
recommended by the Clinical and Laboratory Standards Institute (CLSI).22,23 Stationary phase 112 
cultures were diluted 1:100 in fresh media and cultured at 37°C with agitation until reaching 113 
exponential growth. Then, bacterial inoculum was standardized up to a final concentration of 114 
  
5.105 cfu/mL and exposed to serially diluted concentrations of antibiotics. Gentamicin and 115 
vancomycin were tested for Gram-positive bacteria. Gentamicin and amikacin were tested for 116 
Gram-negative bacteria. MIC was defined as the first well with no visible bacterial growth. 117 
The final value was the mean of 3 independent experiments. We used CLSI thresholds to 118 
define if a strain was susceptible or resistant towards one of the tested antibiotics (Table 1).23  119 
 120 
In vitro biofilm formation. In vitro biofilms were grown in triplicate for 24 hours (S. aureus, 121 
S. epidermidis, E. faecalis and Enterobacteriaceae) or 48 hours (P. aeruginosa) on UV-122 
sterilized polyvinyl chloride (PVC) 96-well plates (Thermo Scientific, Rochester, NY), as 123 
previously described.13,24 Briefly, stationary phase cultures were diluted up to OD600nm of 0.05 124 
in fresh media and 100µL of this inoculum was used in each well. Gram-positive bacterial 125 
biofilms were grown in TSB supplemented with 0.25% (or 0.5% for E. faecalis) glucose. 126 
Gram-negative bacterial biofilms were grown in LB broth. After 24 hours (or 48 hours for P. 127 
aeruginosa), planktonic bacteria were removed by 1X PBS washing and biofilms treated for 128 
24 hours using different lock solutions (see below). After 24 hours, each well was washed 129 
twice with 1X PBS to remove planktonic bacteria and excess antibiotics and surviving cfu 130 
were quantified with a vigorous step of pipetting up and down in order to detach all biofilm 131 
bacteria from the surface of the wells. cfu were compared to 24h biofilms and expressed as % 132 
of survival.13,24 For S. aureus, coagulase-negative staphylococci and Enterobacteriaceae, we 133 
decided to retain only the 4 most tolerant strains (i.e. the strains with the highest percentage of 134 
bacterial survival) after a 24-h exposure to the bactericidal antibiotic gentamicin at 5 mg/mL, 135 
a concentration that is usually recommended as ALT (Supplementary Figure 2).8 Then, 136 
biofilms formed by the selected strains were treated using the same procedure with the 137 
following combinations: fresh media (control), gentamicin alone (5 mg/mL), EDTA alone (30 138 
mg/mL), L-arginine alone (0.4%), gentamicin (5 mg/mL) + EDTA (30 mg/mL) 139 
  
(GEN+EDTA), gentamicin (5 mg/mL) + L-arginine (0.4%) (GEN+L-arg). We also tested 140 
amikacin (5 mg/mL, for Gram-negative bacteria) or vancomycin (5 mg/mL, for Gram-141 
positive bacteria) alone or associated with EDTA (30 mg/mL).   142 
 143 
Statistical analysis. Each experiment was performed at least 3 times. Wilcoxon Mann-144 
Whitney test (included in Graphpad Prism Version 5.04) was used to compare mortality of 145 
biofilm bacteria between each type of treatment. Different treatment groups were considered 146 
statistically different if p values were lower than 0.05. The combination of an antibiotic and 147 
an adjuvant was considered active if biofilm survival was significantly reduced, when 148 
compared with antibiotic treatment alone. 149 
150 
  
Results 151 
EDTA-gentamicin lock is active against most tested clinical strains.  152 
We first compared the activity of gentamicin alone or GEN+EDTA locks against in vitro 153 
biofilm formed in microtiter plate assay by clinical strains responsible for CRBSI. We 154 
observed that all tested strains exhibited various degrees of tolerance towards antibiotics with 155 
0.01 to 50% of bacterial survival after a 24-h exposure to 5 mg/mL of gentamicin. Among the 156 
18 tested clinical strains, all but one P. aeruginosa strain exhibited a significant reduction of 157 
bacterial survival when disodium EDTA was added to gentamicin (Figure 1 to 5). The effect 158 
was also seen against highly tolerant strains, i.e. strains with high % of survival when exposed 159 
to high concentration of gentamicin alone. For instance, even if 50% of S. epidermidis strain 160 
50 biofilm bacteria survived after gentamicin challenge, the adjunction of EDTA increased 161 
bacterial mortality by 3-log (Figure 2A). Similar findings were made with highly tolerant 162 
strains of S. aureus (Figure 1A), E. faecalis (Figure 3A), P. aeruginosa (Figure 4D) and 163 
Enterobacteriaceae (Figure 5A and D). Lastly, the effect could also be seen against resistant 164 
strains, such as P. aeruginosa strain 32.  165 
Taken together, these results demonstrate that the adjunction of disodium EDTA significantly 166 
increases the effect of gentamicin against biofilms formed by almost all tested strains of 167 
bacterial pathogens responsible for CRBSI, including highly tolerant or resistant bacteria.  168 
 169 
The combination of L-arginine and gentamicin is active against all tested pathogens but 170 
S. epidermidis. 171 
Against S. aureus, E. faecalis, Enterobacteriaceae and P. aeruginosa, GEN+L-arg lock is 172 
active against almost all tested strains, with the exception of one strain of K. pneumoniae 173 
(Figure 1, 3, 4 and 5). Conversely, the adjunction of L-arginine to gentamicin did not 174 
increase the effect of antibiotic alone against S. epidermidis (Figure 2). Against S. aureus or 175 
  
P. aeruginosa, no significant difference could be seen regarding the reduction of biofilm 176 
survival comparing GEN+EDTA and GEN+L-arg locks (Figure 1 and 4). 177 
Taken together, these results demonstrate that even if GEN+L-arg lock is active against S. 178 
aureus, E. faecalis, Enterobacteriaceae and P. aeruginosa, it does not significantly increase 179 
the effect of gentamicin against coagulase-negative staphylococci. 180 
 181 
Use of EDTA also increases the efficiency of alternative antibiotic locks. 182 
We then tested the effect of vancomycin or amikacin alone or associated with EDTA against 183 
our array of clinical strains to compare their activity on antibiotic resistant or susceptible 184 
bacteria.19,20 We focused our study on EDTA, as it exhibited the wider spectrum of action. 185 
Against S. aureus or E. faecalis, gentamicin was associated with higher mortality of biofilm 186 
bacteria, as compared with vancomycin in all tested strains but 1 S. aureus (Figure 1 and 3). 187 
Conversely, against S. epidermidis, vancomycin was more active than gentamicin in 2 strains, 188 
less active in 1 strain and equally active in 1 strain (Figure 2). Against Gram-positive 189 
bacteria, the adjunction of EDTA increased mortality of biofilm bacteria, in all cases (Figure 190 
1 to 3). However, in the case of S. aureus, the effect was related only to the effect of EDTA 191 
alone, as demonstrated by the absence of a significant difference between EDTA and 192 
VAN+EDTA (Figure 1). Conversely, against coagulase-negative staphylococci and E. 193 
faecalis, VAN+EDTA was more active than EDTA alone (Figure 2 and 3). 194 
Against Gram-negative bacteria, amikacin was as active as gentamicin in 5/8 strains and more 195 
active than gentamicin in 3/8 strains (Figure 4 and 5). The adjunction of EDTA to amikacin 196 
increased the mortality of biofilm bacteria in 50% of cases (2 strains of P. aeruginosa and 2 197 
strains of Enterobacteriaceae).  198 
Taken together, these results demonstrated that the adjunction of EDTA to vancomycin or 199 
amikacin increased mortality of biofilm bacteria in a majority of clinical strains.  200 
201 
  
Discussion  202 
The recent identification of gentamicin-based catheter locks (associated with EDTA or L-203 
arginine) leading to fast and long-lasting eradication of biofilms formed by Gram-positive and 204 
Gram-negative pathogens suggests that these locks could be successfully used in clinical 205 
situations.12,13 However, these adjuvant strategies were only tested on a limited number of 206 
laboratory bacterial strains and testing the efficiency of these locks against a wide and 207 
clinically relevant panel of strains responsible for CRBSI constitutes a mandatory preliminary 208 
towards potential clinical study. Here, we tested these 2 adjuvant strategies combining EDTA 209 
or L-arginine with aminoglycosides against 18 strains collected during a prospective study, 210 
specifically designed to study the clinical outcome after CRBSI.18 We demonstrated that the 211 
adjuvant gentamicin + EDTA strategy was effective on a broader spectrum of Gram-positive 212 
and Gram-negative bacterial pathogens as compared to the adjuvant gentamicin + L-arginine 213 
strategy. Additionally, we showed that efficiency of other aminoglycosides such as amikacin 214 
(in Gram-negative bacteria) and vancomycin (in Gram-positive bacteria) are also potentiated 215 
by EDTA adjunction. 216 
More specifically, we observed that the adjunction of EDTA significantly increases the effect 217 
of gentamicin against all tested strains but one P. aeruginosa. However, in this later strain, we 218 
also observed a trend toward a higher activity when GEN+EDTA was compared to 219 
gentamicin alone (p=0.073). We previously demonstrated that GEN+EDTA used as ALT was 220 
amenable to clinical studies as it eradicated biofilms formed by bacterial nosocomial 221 
pathogens.12 Furthermore, another group also reported that GEN+EDTA was a promising 222 
combination for biofilm eradication.15 The potentiation of gentamicin effect is very likely due 223 
to the ability of cation chelator to destabilize the biofilm matrix or because of a direct 224 
bactericidal effect of EDTA against biofilm bacteria.14,25 In the present study, the fact that we 225 
do not reach biofilm eradication during in vitro experiments is very likely due to the short 226 
  
course of lock treatment (24 hours), as compared to in vivo experiments (at least 5 days), as 227 
well as the presence of the immune system in vivo that may favor clearance of biofilm 228 
bacteria when weakened by the treatment. To date, no in vitro, in vivo or clinical data support 229 
the use of ALT during only one day. So far, a possible limitation for the use of EDTA is its 230 
commercial availability that is restricted to its association with minocycline. 231 
 We also tested another strategy using L-arginine as an adjuvant to gentamicin in order 232 
to increase bacterial persisters’ mortality within biofilms.13 Whereas L-arginine efficiently 233 
increased gentamicin activity against most tested bacteria, we did not observe any gentamicin 234 
potentiation against S. epidermidis. As S. epidermidis is a frequent pathogen in case of 235 
CRBSI, this limitation is important and should be taken into account before considering any 236 
clinical studies. One possible explanation regarding this observation is the frequent carriage 237 
of ACME (arginine catabolic mobile element) by coagulase-negative staphylococci. ACME 238 
frequently includes arc, a gene cluster encoding a complete additional arginine deiminase 239 
pathway.26,27 ACME is found in more than 65% of methicillin-susceptible or resistant S. 240 
epidermidis strains.26,28 Hence, one can hypothesize that, in S. epidermidis, increased arginine 241 
metabolism could reduce its adjuvant effect. Indeed, ACME is less frequently found in S. 242 
aureus, as compared with coagulase-negative staphylococci.26,29 243 
 We also observed an important variability between different strains within a single 244 
species regarding the effects of antibiotics alone or the magnitude of the synergistic effect. 245 
This observation highlights the importance of testing any candidate compound or combination 246 
against multiple strains representative of each bacterial species to rule out any strain-specific 247 
effect. 248 
Three percents of methicillin-susceptible S. aureus and 11% of methicillin-resistant S. 249 
aureus were found to be gentamicin-resistant in a recent survey of hospital-acquired 250 
infections in Texas.19 In Canadian intensive care units, 8% of E. coli and 32% of P. 251 
  
aeruginosa were gentamicin-resistant.20 More strikingly, 60% of S. epidermidis responsible 252 
for bloodstream infections in Germany were gentamicin-resistant.30 Thus, identifying the 253 
most active approach against gentamicin-resistant bacteria is essential. In vivo, we previously 254 
showed that a 5-day GEN+EDTA ALT procedure allows the eradication of biofilm formed by 255 
gentamicin-resistant S. aureus.12 Here, we also noticed that a synergistic effect could be seen 256 
in vitro between gentamicin and EDTA against gentamicin-resistant or intermediate strains, 257 
as shown with P. aeruginosa strain 32 and 35 or S. epidermidis strain 50. However, even with 258 
these strains, GEN+EDTA was still the most active combination. These data suggest that 259 
GEN+EDTA ALT could be used in case of gentamicin-resistant strain, even if more 260 
experimental data are required to confirm what is the best therapeutic strategy in this 261 
situation. Additionally, we wanted to study the efficiency of other clinically relevant 262 
combinations, such as AMK+EDTA against Gram-negative bacteria or VAN+EDTA against 263 
Gram-positive bacteria. Against Gram-positive bacteria, we noticed that the adjunction of 264 
EDTA increased biofilm mortality, in all cases. An effect was also seen against S. epidermidis 265 
strain 53, despite a high vancomycin MIC, confirming that planktonic bacteria-based 266 
antibiotic susceptibility tests do not predict biofilm tolerance towards antibiotics. Against 267 
Gram-negative bacteria, a synergy between EDTA and amikacin was noticed in 50% of cases 268 
and no antagonism was seen. Such an effect was also observed even in the case of an 269 
amikacin-intermediate strain, such as P. aeruginosa strain 32. Such locks could potentially be 270 
used in case of resistance towards gentamicin. 271 
Few studies compared the activity of gentamicin to other drugs against biofilms using 272 
a standardized method. Against S. epidermidis and S. aureus, it has been shown that 273 
vancomycin was more active that gentamicin in biofilm setting.31,32 However, in vivo, 274 
gentamicin at 40 mg/mL was shown to be more active that vancomycin at 2 mg/mL against S. 275 
aureus.33 In the present study, gentamicin was more active than vancomycin against S. aureus 276 
  
or E. faecalis biofilms. The results were less clear-cut in the case of S. epidermidis, since 277 
vancomycin was more active than gentamicin in 2 strains, less active in 1 strain and equally 278 
active in 1 strain. Against Gram-negative bacteria, amikacin was as active as gentamicin in 5 279 
out of 8 strains but more active than gentamicin in the remaining 3 strains. However, no other 280 
in vitro or in vivo study compared the activity of gentamicin to amikacin as locks against 281 
Gram-negative bacteria. 282 
To note, the characteristics of the surface that is used for biofilm formation might 283 
influence the phenotype of tolerance towards antibiotics. In our case, the surface of the 96-284 
well PVC plates differs from that of a silicone catheter and might be a limitation of the 285 
present study. Other technical limitations are the use of vigorous pipetting up and down for 286 
cfu quantification and the assessment of bacterial mortality at a single time point.  287 
 288 
In conclusion, our data demonstrate that EDTA acts synergistically with gentamicin to kill 289 
biofilms formed by bacterial strains responsible for CRBSI. A clinical study assessing the 290 
potential of GEN+EDTA as a lock therapy is now warranted.   291 
 292 
293 
  
Acknowledgements 294 
None. 295 
 296 
Fundings 297 
This work was supported by Institut Pasteur grant and by the French Government's 298 
Investissement d'Avenir program, Laboratoire d'Excellence "Integrative Biology of Emerging 299 
Infectious Diseases" (grant n°ANR-10-LABX-62-IBEID) and from Fondation pour la 300 
Recherche Médicale grant "Equipe FRM DEQ20140329508". D.L. was supported by a grant 301 
from the AXA Research Fund.  302 
 303 
 304 
Transparency declarations 305 
Conflict of interest: none to declare 306 
  16 
References 
1 Messing B, Peitra-Cohen S, Debure A, et al. Antibiotic-lock technique: a new 
approach to optimal therapy for catheter-related sepsis in home-parenteral nutrition patients. 
JPEN J Parenter Enteral Nutr 1988; 12: 185-9. 
2 Fernandez-Hidalgo N, Almirante B, Calleja R, et al. Antibiotic-lock therapy for long-
term intravascular catheter-related bacteraemia: results of an open, non-comparative study. J 
Antimicrob Chemother 2006; 57: 1172-80. 
3 Fortun J, Grill F, Martin-Davila P, et al. Treatment of long-term intravascular catheter-
related bacteraemia with antibiotic-lock therapy. J Antimicrob Chemother 2006; 58: 816-21. 
4 Lebeaux D, Fernandez-Hidalgo N, Chauhan A, et al. Management of infections related 
to totally implantable venous-access ports: challenges and perspectives. Lancet Infect Dis 
2014; 14: 146-59. 
5 Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: a common cause of 
persistent infections. Science 1999; 284: 1318-22. 
6 Lebeaux D, Ghigo JM, Beloin C. Biofilm-Related Infections: Bridging the Gap 
between Clinical Management and Fundamental Aspects of Recalcitrance toward Antibiotics. 
Microbiol. Mol. Biol. Rev. 2014; 78: 510-43. 
7 Lewis K. Multidrug tolerance of biofilms and persister cells. Current topics in 
microbiology and immunology 2008; 322: 107-31. 
8 Mermel LA, Allon M, Bouza E, et al. Clinical practice guidelines for the diagnosis 
and management of intravascular catheter-related infection: 2009 Update by the Infectious 
Diseases Society of America. Clin Infect Dis 2009; 49: 1-45. 
9 Reimund JM, Arondel Y, Finck G, et al. Catheter-related infection in patients on home 
parenteral nutrition: results of a prospective survey. Clin Nutr 2002; 21: 33-8. 
  17 
10 Rijnders BJ, Van Wijngaerden E, Vandecasteele SJ, et al. Treatment of long-term 
intravascular catheter-related bacteraemia with antibiotic lock: randomized, placebo-
controlled trial. J Antimicrob Chemother 2005; 55: 90-4. 
11 Funalleras G, Fernandez-Hidalgo N, Borrego A, et al. Effectiveness of antibiotic-lock 
therapy for long-term catheter-related bacteremia due to Gram-negative bacilli: a prospective 
observational study. Clin Infect Dis 2011; 53: e129-32. 
12 Chauhan A, Lebeaux D, Ghigo JM, et al. Full and broad-spectrum in vivo eradication 
of catheter-associated biofilms using gentamicin-EDTA antibiotic lock therapy. Antimicrob 
Agents Chemother 2012; 56: 6310-8. 
13 Lebeaux D, Chauhan A, Letoffe S, et al. pH-Mediated Potentiation of 
Aminoglycosides Kills Bacterial Persisters and Eradicates In Vivo Biofilms. J Infect Dis 
2014; 210: 1357-66. 
14 Turakhia MH, Cooksey KE, Characklis WG. Influence of a calcium-specific chelant 
on biofilm removal. Appl Environ Microbiol 1983; 46: 1236-8. 
15 Bookstaver PB, Williamson JC, Tucker BK, et al. Activity of novel antibiotic lock 
solutions in a model against isolates of catheter-related bloodstream infections. Ann 
Pharmacother 2009; 43: 210-9. 
16 Raad II, Fang X, Keutgen XM, et al. The role of chelators in preventing biofilm 
formation and catheter-related bloodstream infections. Curr Opin Infect Dis 2008; 21: 385-
92. 
17 Chauhan A, Lebeaux D, Decante B, et al. A rat model of central venous catheter to 
study establishment of long-term bacterial biofilm and related acute and chronic infections. 
PloS one 2012; 7: e37281. 
  18 
18 Lebeaux D, Larroque B, Gellen-Dautremer J, et al. Clinical outcome after a totally 
implantable venous access port-related infection in cancer patients: a prospective study and 
review of the literature. Medicine (Baltimore) 2012; 91: 309-18. 
19 Hulten KG, Kaplan SL, Lamberth LB, et al. Hospital-acquired Staphylococcus aureus 
infections at Texas Children's Hospital, 2001-2007. Infect Control Hosp Epidemiol 2010; 31: 
183-90. 
20 Zhanel GG, DeCorby M, Laing N, et al. Antimicrobial-resistant pathogens in intensive 
care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 
2005-2006. Antimicrob Agents Chemother 2008; 52: 1430-7. 
21 Bertani G. Lysogeny at mid-twentieth century: P1, P2, and other experimental 
systems. Journal of Bacteriology 2004; 186: 595-600. 
22 Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial 
Susceptibility Tests for Bacteria that Grow Aerobically; Approved Standard-Eigth Edition. 
M07-A8. CLSI, Wayne, PA, USA, 2009.  
23 Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial 
Susceptibility Testing; Twentieth Informational Supplement. M100-S20. CLSI, Wayne, PA, 
USA, 2010.  
24 Bernier SP, Lebeaux D, DeFrancesco AS, et al. Starvation, together with the SOS 
response, mediates high biofilm-specific tolerance to the fluoroquinolone ofloxacin. PLoS 
Genet 2013; 9: e1003144. 
25 Banin E, Brady KM, Greenberg EP. Chelator-induced dispersal and killing of 
Pseudomonas aeruginosa cells in a biofilm. Appl Environ Microbiol 2006; 72: 2064-9. 
26 Barbier F, Lebeaux D, Hernandez D, et al. High prevalence of the arginine catabolic 
mobile element in carriage isolates of methicillin-resistant Staphylococcus epidermidis. J 
Antimicrob Chemother 2011; 66: 29-36. 
  19 
27 Diep BA, Otto M. The role of virulence determinants in community-associated MRSA 
pathogenesis. Trends Microbiol 2008; 16: 361-9. 
28 Miragaia M, de Lencastre H, Perdreau-Remington F, et al. Genetic diversity of 
arginine catabolic mobile element in Staphylococcus epidermidis. PloS one 2009; 4: e7722. 
29 Planet PJ, LaRussa SJ, Dana A, et al. Emergence of the epidemic methicillin-resistant 
Staphylococcus aureus strain USA300 coincides with horizontal transfer of the arginine 
catabolic mobile element and speG-mediated adaptations for survival on skin. mBio 2013; 4: 
e00889-13. 
30 von Eiff C, Reinert RR, Kresken M, et al. Nationwide German multicenter study on 
prevalence of antibiotic resistance in staphylococcal bloodstream isolates and comparative in 
vitro activities of quinupristin-dalfopristin. J Clin Microbiol 2000; 38: 2819-23. 
31 Curtin J, Cormican M, Fleming G, et al. Linezolid compared with eperezolid, 
vancomycin, and gentamicin in an in vitro model of antimicrobial lock therapy for 
Staphylococcus epidermidis central venous catheter-related biofilm infections. Antimicrob 
Agents Chemother 2003; 47: 3145-8. 
32 Lee JY, Ko KS, Peck KR, et al. In vitro evaluation of the antibiotic lock technique 
(ALT) for the treatment of catheter-related infections caused by staphylococci. J Antimicrob 
Chemother 2006; 57: 1110-5. 
33 Fernández-Hidalgo N, Gavaldà J, Almirante B, et al. Evaluation of linezolid, 
vancomycin, gentamicin and ciprofloxacin in a rabbit model of antibiotic-lock technique for 
Staphylococcus aureus catheter-related infection. J Antimicrob Chemother 2010; 65: 525-30. 
 
 
